[PERSON]
Arjun Agarwal
Featured in 2 tracked stories · first seen
Situations
Oruka Therapeutics drug development expansion
2 clusters · 5 sources · last updated
Latest: Oracle and Sumitomo Mitsui see notable stock transactions
Oruka Therapeutics has expanded the development rights for its lead IL-23 program, ORKA-001, to include inflammatory bowel disease (IBD) following an amended license agreement with Paragon Therapeutics. The company is cu
Oncolytics Biotech analyst rating shifts
2 clusters · 2 sources · last updated
Latest: Oncolytics Biotech and Oruka Therapeutics see analyst rating shifts and modest stock moves
On July 9, Oncolytics Biotech shares jumped about 16% after analysts offered divergent opinions on the stock’s rating. By July 30, the company’s share price moved only modestly, up 0.2% to $0.7530, with analysts split: W